Pfizer’s latest-generation pneumococcal conjugate vaccine is in line to reach more people in Latin America and the Caribbean through a joint effort with Argentina’s government, The Pan American Health Organization (PAHO) and Argentinian drugmaker Sinergium Biotech.
Under the initiative, Buenos Aires-based Sinergium will produce Pfizer’s Prevnar 20 in Argentina, with doses expected to be ready to roll out by 2026. In the meantime, countries across the Americas region will be able to access the vaccine at “competitive prices” through PAHO’s Regional Revolving Funds for Access to Vaccines, a program that allows countries to make joint vaccine purchases, PAHO explained in a release.
“PAHO is committed to boosting regional production of sustainable, innovative technologies by…